AI-generated from publicly available materials.Everlywell has introduced Clairity AI, a groundbreaking tool for assessing breast cancer risk from routine mammograms, marking a significant advancement in digital health.
This launch coincides with Breast Cancer Awareness Month, enhancing the accessibility of Clairity Breast, the first FDA-authorized AI to evaluate a woman's five-year risk of developing breast cancer based on mammography screenings. The collaboration between Everlywell, led by Julia Cheek, and Clairity, founded by Dr. Connie Lehman, highlights the impact of female leadership in health technology.
Breast cancer remains a critical health issue, with over 2.3 million women diagnosed globally each year, and more than 370,000 in the U.S. alone. Notably, 85% of breast cancer cases occur in women without a family history of the disease, underscoring the necessity for improved risk assessment tools like Clairity Breast. This AI technology detects subtle tissue patterns in standard 2D mammograms that may indicate future cancer risk, even when images appear normal to radiologists.
The timing of this rollout is crucial, as recent updates to the National Comprehensive Cancer Network (NCCN) guidelines have recommended AI-based assessments to identify women at increased risk starting at age 35. By integrating Clairity AI into its platform, Everlywell allows patients to gain valuable insights from their recent mammograms, empowering them to engage more effectively with their healthcare providers regarding screening and risk reduction strategies.